Boston Therapeutics Completes Enrollment for BTI-320

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boston Therapeutics Completes Enrollment for BTI-320 Clinical Trial

MANCHESTER, NH--(Marketwired - Oct 6, 2015) - Boston Therapeutics, Inc. ( OTCQB : BTHE ) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), completed enrollment for the clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial had 60 pre-diabetic patients.

This key developmental trial, being conducted in Hong Kong and the associated endpoints are pivotal for concluding the BTI-320 registration in mainland China. This clinical trial is supplemental to an on-going separate clinical trial, being conducted in mainland China. It is expected to be completed by year end and the overall dossier for approval is targeted to be submitted in January 2016 for pending country wide approval in the first half of 2016. BTI-320 is planned to address and benefit a population of 495,000,000 pre-diabetic people in China ( JAMA . 2013 Sep 4;310(9):948-59 ) and 50% of the entire population in the USA, who are pre-diabetic and diabetic ( JAMA . 2015;314(10):1021-1029 ) and could make a significant contribution to controlling healthcare costs.

Enrollment in the CUHK first trial was completed ahead of schedule and is expected to confirm the assessment of prevention biomarker parameters associated with postprandial glucose (PPG) spikes measured with Continuous Glucose Monitoring (CGM) device, Fructose accumulation (Fructosamine blood testing) and HbA1c (Glycated Hemoglobin). PPG maximum amplitude peaking and Fructosamines appears to be a major detriment and predicament to lowering HbA1c and forestalling the onset and the advancement of Type 2 Diabetes without the hypoglycemic threat possible with many of the compounds presently associated with diabetes treatment.

The Chinese FDA process is a major focus of APC's alliance partnership in Asia, where they are piloting clinical marketing education programs, specifically in Korea, Hong Kong, Singapore, and most recently Japan. APC has under license from Boston Therapeutics Inc. 15 countries in South East Asia.

David Platt, Ph.D., CEO of Boston Therapeutics, said, "BTI-320 is the only drug candidate in development to safely block Glucose, Fructose and other sugars simultaneously with a single molecular structure. With over 150 patients treated to date, there are no Serious Adverse Effects (SAE) observed. We are fortunate to have APC as a financial partner to conduct and fund these and other studies and look forward to commercializing BTI-320 where we may help many people to manage this world health mandate to manage blood sugar."

Boston Therapeutics developed BTI-320 and markets it through APC in Asia. BTI-320 is a non-systemic compound (working only in the intestine not in blood), designed to block the increase of post-meal elevation of blood Glucose, Fructose and other key Sugars. BTI-320 is to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose Fructose and other sugars for absorption into the bloodstream.

Dr. Juliana CN Chan, PRCP is the lead principal investigator and the lead clinical site is the Department of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital.

About Advance Pharmaceutical Company, Ltd.

Advance Pharmaceutical Company is a leading Hong Kong-based pharmaceutical company. Advance Pharmaceutical Company currently sells more than 400 types of licensed pharmaceutical products, consisting of prescription and over the counter products to local dispensaries, medicine shops, clinics and hospitals, as well as chain stores, such as 7-11, Wellcome, Park-N-Shop, Mannings and Watson's. Outside of Hong Kong, Advance Pharmaceutical Company has been building and maintaining its marketing network in Macau since 1983 and has many years of experience in exporting and distributing pharmaceutical products to China. Currently, Advance Pharmaceutical Company's products penetrate 90% of dispensaries and drug stores in Macau. Additional information is available at http://www.apc.com.hk/aboutus.php .

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com and www.clinicaltrials.gov .

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "May," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others that our plans, expectations and goals regarding our clinical development of BTI-320 are subject to factors beyond our control. We can provide no assurance that we or our commercial partners will be able to generate market demand for BTI-320, and thus we may not be able to generate revenue from sales.

Moreover, we have incurred operating losses since our inception, and our ability to successfully develop, market, manufacture, distribute and sell drugs or over-the-counter products may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2014, and our subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact: Boston Therapeutics, Inc. David Platt, PhD Chief Executive Officer Phone: 603-935-9799 Email: david.platt@bostonti.com www.bostonti.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Eaton Corp's Options Trading Insights and Market Analysis

Updated Category News Views 116

Understanding Eaton Corp's Options Trading Trends Recently, financial analysts have noticed a significant bearish trend when it comes to options trading for Eaton Corp (NYSE: ETN). Investigating the history of options trades has revealed insights into the market sentiment surrounding this industrial giant. A thorough analysis showed that a mere 11% of traders exhibited...

Continue Reading
Celebrating Community Resilience After Pacific Palisades Fires

Updated Category News Views 207

Community Resilience Shines in Pacific Palisades The recent reopening of the Casa Gateway affordable housing complex in Pacific Palisades brings a heartwarming sense of relief to many residents who faced the devastating impact of fires. Amidst the recovery efforts, stories of gratitude and hope shine through, demonstrating the importance of community support and...

Continue Reading
Stellantis Makes Bold Move with $41 Million Investment for Efficiency

Updated Category News Views 225

Stellantis Invests $41 Million for Enhanced Parts Delivery Stellantis (NASDAQ: STLA), the parent organization of popular automotive brands such as Jeep and Dodge, is taking significant steps towards improving its logistics capabilities with a substantial $41 million investment. This financial commitment is part of a broader strategy to modernize its parts distribution...

Continue Reading
Navigating the Shifts in Money Market Dynamics and Bank Reserves

Updated Category News Views 137

Understanding Current Dynamics in Money Markets The landscape of liquidity in the money markets is currently characterized by ample conditions. However, experts anticipate a reduction in bank reserves in the months ahead, leading to a potential tightening of conditions. With ongoing activity in market repurchase agreements (repo) and a robust issuance of treasury bills,...

Continue Reading
Harnessing AI and Human Intelligence for Personal Growth

Updated Category News Views 329

AI Happiness Accelerator Empowers Personal Growth Imagine if you could optimize your thoughts and emotions just like improving a website’s performance. The AI Happiness Accelerator (AHA) aims to do exactly that by leveraging cutting-edge Generative AI tools. Co-founder and Chief Information Officer Amy Chang emphasizes that success in all areas—personal, relational,...

Continue Reading